ENDRA Life Sciences (NDRA) Liabilities and Shareholders Equity (2016 - 2021)
ENDRA Life Sciences (NDRA) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $15.3 million as the latest value for Q3 2021.
- Quarterly Liabilities and Shareholders Equity rose 185.65% to $15.3 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $51.5 million through Dec 2021, up 140.59% year-over-year, with the annual reading at $8.8 million for FY2020, 22.14% up from the prior year.
- Liabilities and Shareholders Equity for Q3 2021 was $15.3 million at ENDRA Life Sciences, down from $17.2 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $18.9 million in Q1 2021, with the low at $545126.0 in Q1 2017.
- Average Liabilities and Shareholders Equity over 5 years is $6.8 million, with a median of $5.4 million recorded in 2020.
- The sharpest move saw Liabilities and Shareholders Equity skyrocketed 1147.8% in 2017, then plummeted 82.73% in 2018.
- Over 5 years, Liabilities and Shareholders Equity stood at $6.1 million in 2017, then increased by 17.95% to $7.2 million in 2018, then decreased by 0.64% to $7.2 million in 2019, then increased by 22.14% to $8.8 million in 2020, then skyrocketed by 74.72% to $15.3 million in 2021.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $15.3 million, $17.2 million, and $18.9 million for Q3 2021, Q2 2021, and Q1 2021 respectively.